Equine Botulinum Neurotoxin G Immune FAB2

Generic Name: Equine Botulinum Neurotoxin G Immune FAB2

Brand Names: BAT

Drug Type: Biotech

Unique Ingredient Identifier: 943578J0XG

Background: Equine Botulinum Neurotoxin G Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype G. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.

Indication: Equine Botulinum Neurotoxin G Immune FAB2 is indicted for use in documented or suspected exposure to botulinum toxin serotype G in adults and pediatric patients [FDA Label].

Associated Conditions: Symptomatic Botulism, Symptomatic Botulism caused by Clostridium botulinum serotype G

Clinical Trials

A Clinical Study of Bacillus Coagulans in Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation

Not Applicable

Not yet recruiting

Conditions: Acute Graft-versus-host Disease

Interventions: Drug: bacillus coagulans combined with the best treatment options for preventing aGVHD
Drug: BAT

First Posted Date: 2024-09-13

Last Posted Date: 2024-09-13

Lead Sponsor: Yamin Fan

Target Recruit Count: 508

Registration Number: NCT06593834

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants with Steroid-Refractory Acute Graft Versus Host Disease

Phase 2

Recruiting

Conditions: Steroid-refractory Acute Graft-versus-host Disease

Interventions: Biological: MC0518
Biological: BAT

First Posted Date: 2023-10-10

Last Posted Date: 2025-01-14

Lead Sponsor: medac GmbH

Target Recruit Count: 48

Registration Number: NCT06075706

Locations: 🇫🇷
CHU de Bordeaux - Hopital des Enfants, Bordeaux, France
🇫🇷
CHU de Marseille-Hopital de la Timone, Marseille, France
🇫🇷
CHU Grenoble Alpes - Hopital Couple Enfant (HCE), La Tronche, France

and more 35 locations

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

Phase 3

Recruiting

Conditions: Hospital-acquired Bacterial Pneumonia
Complicated Intra-abdominal Infection
Ventilator-associated Bacterial Pneumonia
Complicated Urinary Tract Infection
Acute Pyelonephritis

Interventions: Drug: BAT
Drug: co-administration of cefepime and nacubactam
Drug: co-administration of aztreonam and nacubactam

First Posted Date: 2023-06-15

Last Posted Date: 2025-05-09

Lead Sponsor: Meiji Seika Pharma Co., Ltd.

Target Recruit Count: 150

Registration Number: NCT05905055

Locations: 🇯🇵
Meiji Research Site, Nankoku, Kochi, Japan

PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB

Phase 2

Completed

Conditions: Ventilator Associated Pneumonia

Interventions: Drug: BV100 plus Polymyxin B
Drug: BAT

First Posted Date: 2023-01-17

Last Posted Date: 2025-01-14

Lead Sponsor: BioVersys AG

Target Recruit Count: 39

Registration Number: NCT05685615

Locations: 🇭🇺
University of Debrecen Clinical Center, Debrecen, Hungary
🇭🇺
University Educational Hospital, Miskolc, Hungary
🇭🇺
Fejer County St. Gyorgy University Teaching Hospital, Szekesfehervar, Hungary

and more 13 locations

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Phase 2

Recruiting

Conditions: Gram-negative Bacterial Infections

Interventions: Drug: ATM-AVI
Drug: BAT

First Posted Date: 2022-12-06

Last Posted Date: 2025-05-14

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT05639647

Locations: 🇹🇷
Cukurova Universty, Sarçam, Adana, Turkey
🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸
Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York, United States

and more 29 locations

Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients

Phase 2

Terminated

Conditions: Coronavirus Infection
ARDS, Human

Interventions: Drug: BAT
Drug: Bevacizumab

First Posted Date: 2021-07-08

Last Posted Date: 2021-09-05

Lead Sponsor: Maimónides Biomedical Research Institute of Córdoba

Target Recruit Count: 21

Registration Number: NCT04954014

Locations: 🇪🇸
Hospital Universitario Reina Sofía, Córdoba, Córdona, Spain

Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy

Phase 3

Recruiting

Conditions: Steroid-refractory Acute Graft-versus-host Disease

Interventions: Biological: MC0518
Biological: BAT

First Posted Date: 2020-11-16

Last Posted Date: 2024-12-10

Lead Sponsor: medac GmbH

Target Recruit Count: 210

Registration Number: NCT04629833

Locations: 🇫🇷
Centre Hospitalier Universitaire (CHU) Amiens-Picardie - Hopital Sud, Amiens, France
🇫🇷
CHU Jean Minjoz, Besancon, France
🇫🇷
CHU de Nantes - Hotel Dieu, Nantes, France

and more 39 locations

Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome

Phase 2

Completed

Conditions: Cytokine Storm
SARS (Severe Acute Respiratory Syndrome)
COVID19
SARS-CoV 2
Cytokine Release Syndrome

Interventions: Drug: BAT + Calcifediol
Drug: BAT

First Posted Date: 2020-04-29

Last Posted Date: 2023-03-03

Lead Sponsor: Maimónides Biomedical Research Institute of Córdoba

Target Recruit Count: 517

Registration Number: NCT04366908

Locations: 🇪🇸
Hospital Universitario Reina Sofía, Cordoba, Spain

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

Phase 3

Terminated

Conditions: Serious Bacterial Infection

Interventions: Combination Product: ATM-AVI
Drug: BAT

First Posted Date: 2018-07-09

Last Posted Date: 2024-02-02

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT03580044

Locations: 🇨🇳
The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
🇨🇳
Hunan Province People's Hospital, Changsha, Hunan, China
🇨🇳
The First Hospital of Kunming, Kunming, China

and more 38 locations

GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: BAT/FF
Drug: BAT
Drug: FF
Drug: FF (MgSt)
Drug: FF/Vilanterol

First Posted Date: 2016-01-28

Last Posted Date: 2017-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 48

Registration Number: NCT02666287

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy